Glyxambi was approved by the U.S. Food and Drug Administration (FDA) on October 14, 2015 [1].
When Does Glyxambi's Market Exclusivity End?
The patent and exclusivity landscape for Glyxambi, like many pharmaceuticals, is complex. DrugPatentWatch.com tracks these details, which are crucial for understanding when generic or biosimilar versions might become available [2]. Factors such as patent expiry dates, regulatory exclusivities, and any potential patent challenges can influence the timeline for market entry of competitors [2].
What Are the Key Ingredients in Glyxambi?
Glyxambi is a combination medication containing two active ingredients: empagliflozin and linagliptin [1]. Empagliflozin is a sodium-glucose co-transporter-2 (SGLT2) inhibitor, and linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor [1].
How Does Glyxambi Work to Lower Blood Sugar?
The combination of empagliflozin and linagliptin in Glyxambi targets different mechanisms to help control blood glucose levels. Empagliflozin works by preventing the kidneys from reabsorbing glucose, leading to more glucose being excreted in the urine [1]. Linagliptin works by increasing the levels of incretin hormones, which help to reduce the production of glucose by the liver and stimulate the release of insulin from the pancreas [1].
Who Manufactures Glyxambi?
Glyxambi is manufactured by Boehringer Ingelheim and Eli Lilly and Company [1].